Floatz logo

Trimetazidine

Hepatocellular Carcinoma

The First Affiliated Hospital of Zhengzhou UniversitySmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

499 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Xaliplatin
Li Qiang
Phase 4BBB
Fluorouracilum
Li Qiang
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Trimetazidine is also rated in:

mitochondrial diseaseActive
BB
Indicative · Phase 4
69 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
B
Indicative · Phase 2
57 / 100
View asset →
ischemic strokeActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →